Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.
- Mehanna, H
- Robinson, M
- Hartley, A
- Kong, A
- Foran, B
- Fulton-Lieuw, T
- Dalby, M
- Mistry, P
- Sen, M
- O'Toole, L
- Al Booz, H
- Dyker, K
- Moleron, R
- Whitaker, S
- Brennan, S
- Cook, A
- Griffin, M
- Aynsley, E
- Rolles, M
- De Winton, E
- Chan, A
- Srinivasan, D
- Nixon, I
- Grumett, J
- Leemans, CR
- Buter, J
- Henderson, J
- Harrington, K
- McConkey, C
- Gray, A
- Dunn, J
- De-ESCALaTE HPV Trial Group
DOIAbstract
Background The incidence of human papillomavirus (HPV)-positive oropharyngeal cancer, a disease affecting younger patients, is rapidly increasing. Cetuximab, an epidermal growth factor receptor inhibitor, has been proposed for treatment de-escalation in this setting to reduce the toxicity of standard cisplatin treatment, but no randomised evidence exists for the efficacy of this strategy.Methods We did an open-label randomised controlled phase 3 trial at 32 head and neck treatment centres in Ireland, the Netherlands, and the UK, in patients aged 18 years or older with HPV-positive low-risk oropharyngeal cancer (non-smokers or lifetime smokers with a smoking history of <10 pack-years). Eligible patients were randomly assigned (1:1) to receiv...
Add to ORKG